| Chronic idiopathic constipation
Motegrity vs Trulance
Side-by-side clinical, coverage, and cost comparison for chronic idiopathic constipation.Deep comparison between: Motegrity vs Trulance with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrulance has a higher rate of injection site reactions vs Motegrity based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trulance but not Motegrity, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Motegrity
Trulance
At A Glance
Oral
Daily
5-HT4 receptor agonist
Oral
Daily
GC-C agonist
Indications
- Chronic idiopathic constipation
- Chronic idiopathic constipation
- irritable bowel syndrome with constipation
Dosing
Chronic idiopathic constipation 2 mg orally once daily; reduce to 1 mg once daily in patients with severe renal impairment (creatinine clearance less than 30 mL/min).
Chronic idiopathic constipation, irritable bowel syndrome with constipation 3 mg taken orally once daily, with or without food.
Contraindications
- History of hypersensitivity to MOTEGRITY (reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed)
- Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, or severe inflammatory conditions of the intestinal tract such as Crohn's disease, ulcerative colitis, and toxic megacolon/megarectum
- Age less than 6 years (risk of serious dehydration)
- Known or suspected mechanical gastrointestinal obstruction
Adverse Reactions
Most common (>=2%) Headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, fatigue
Postmarketing Hypersensitivity reactions (dyspnea, rash, pruritus, urticaria, facial edema); psychiatric disorders including suicide, suicide attempts, suicidal ideation, self-injurious ideation, depression, anxiety, insomnia, nightmares, and visual hallucinations
Most common (>=2%) Diarrhea
Postmarketing Skin itching, hives, rash, vomiting
Pharmacology
Prucalopride is a selective serotonin type 4 (5-HT4) receptor agonist and gastrointestinal prokinetic agent that stimulates colonic peristalsis via high-amplitude propagating contractions, increasing bowel motility without significant activity at 5-HT2A, 5-HT2B, 5-HT3, motilin, or CCK-A receptors.
Plecanatide is a GC-C agonist and structural analog of human uroguanylin that acts locally on the luminal surface of the intestinal epithelium; activation of GC-C increases intracellular and extracellular cGMP, stimulating chloride and bicarbonate secretion via the CFTR ion channel to increase intestinal fluid and accelerate transit.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Motegrity
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Trulance
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (7/12) · Qty limit (9/12)
UnitedHealthcare
Motegrity
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Trulance
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Motegrity
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Trulance
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Motegrity.
No savings programs available for Trulance.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MotegrityView full Motegrity profile
TrulanceView full Trulance profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.